Please assess the completion status of the following clinical trial:

Trial Title: N-methylglycine (Sarcosine) Treatment for Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-55 years~* Fulfilled the DSM-IV criteria of major depressive disorder~* Had a 17-item Hamilton Rating Scale for Depression (HAMD-17)\>or= 18~* No DSM-IV diagnosis of substance abuse or dependence (including alcohol) within the past 6 months~* Had been drug free for \> 3 months~* Physically healthy and had all laboratory parameters within normal limits.~* Agree to participate in the study and provide informed consent~Exclusion Criteria:~* Had history of epilepsy, head trauma or other major neurological or medical diseases~* Had psychotic depression, bipolar I/II disorder, schizophrenia or any other psychotic disorder~* Moderate-severe suicidal risks~* Severe cognitive impairment~* Female subjects who were pregnant, or at risk of pregnancy or lactation~* Initiating or stopping formal psychotherapy within six weeks prior to enrollment~* Had a history of poor response to SSRIs or previously received electroconvulsive therapy~* Had a history of severe adverse reaction to SSRIs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- sarcosine (Type: EXPERIMENTAL): sarcosine
- citalopram (Type: ACTIVE_COMPARATOR): citalopram

Based on this trial design, predict the completion outcome and termination type (if applicable).